Founded in 2020, Bypa Medical Solution (BMS) was born from a strong conviction: technology has now matured enough to enhance healthcare delivery through a more efficient and high-performance real-time device. Created by engineers and physicians combining technological expertise with clinical experience, BMS develops CardioDyn, an innovative medical device designed to overcome the current limitations of cardiac support systems. Since its inception, the company has worked to build technological bridges between the industrial sectors of robotics and digital control, and the urgent need to improve temporary mechanical cardiac support, placing scientific research and development at the heart of its mission. This next-generation device is designed using the most advanced real-time technologies, underpinned by rigorous scientific standards.
BMS's mission is clear: to transform the management of acute heart failure with CardioDyn, a unique innovation that combines physiology, ease of use, and clinical effectiveness.
Chief Executive Officer
President
Medical Director
Finance Expert
The True Pulsatile External Artificial Heart
With stagnant survival rates using standard ECMO devices—ranging from 35% to 50% over the past two decades—CardioDyn provides a concrete solution to one of the greatest challenges in intensive care: improving survival and eligibility for patients with acute heart failure.
Unlike continuous-flow ECMO, it delivers a physiological pulsatile wave synchronized with the ECG in counter-pulsation, ensuring both improved coronary and distal perfusion while enabling cyclic unloading of the cardiac chambers.
Less harmful, easier to implant, and fully self-regulated, it allows for earlier intervention, including outside highly specialized centers.
CardioDyn thus broadens access to life-saving support, offering safer, better-tolerated, and more effective care. By redefining the standards of temporary cardiac support, it paves the way for more accessible and higher-performing medicine.
The CardioDyn Advantage: Revolutionary Technology and Concept for Temporary Cardiac Support
CardioDyn technology generates a regulated pressure wave, controlled by a real-time computer system.
It acts at the optimal moment of each cardiac cycle thanks to precise synchronization with ECG signals.
Equipped with pressure sensors, the system adjusts its support at every heartbeat according to the patient's needs.
During each cycle, CardioDyn delivers the additional pressure and blood flow required.
This approach ensures hemodynamic support that is both physiological and optimized.
CardioDyn: Revolutionizing the Treatment of Heart Disease
CardioDyn's advanced and less aggressive physiological design promotes rapid clinical adoption, establishing a new benchmark for temporary mechanical cardiac support.
Its fully automated regulation makes it the preferred tool for Mobile Cardiac Assistance Units (MCAUs), enabling straightforward prehospital implantation as soon as patient care begins.
Thanks to its pulsatility and synchronization, this unique capability positions CardioDyn as a key pillar in the future of cardiac support. More physiological, self-regulated, and easy to deploy, it provides a safer and better-tolerated solution for patients.
Our team brings together recognized expertise in critical Class III medical devices, clinical research, and healthcare innovation strategy.
United by a common vision, we develop CardioDyn with scientific rigor, regulatory excellence, and clinical ambition, aiming to set a new benchmark in temporary mechanical cardiac support and significantly improve patient care.
Head of Cardiothoracic Surgery Department, La Pitié-Salpêtrière
CEO of Elivia, Former President of Nexans
Professor of Cardiac Surgery, La Pitié-Salpêtrière
Bypa Medical Solutions Invites Strategic Partners to Accelerate Certification, Industrialization, and Commercial Deployment of CardioDyn
This investment opportunity in cutting-edge medical technology, designed to transform the management of acute heart failure, allows you to join a forward-looking vision where scientific innovation, significant medical impact, and potential returns converge.
Would you like to receive more information or request the investor dossier?
Please complete the form below.
